Fig. 3From: Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinomaCost-effectiveness plane. QALY: quality-adjusted life-year; ICER: incremental cost-effectiveness ratio; GDP: gross domestic productBack to article page